Remove 2016 Remove Pharmaceutical research Remove Safety
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed. She is currently CEO and successfully led the IPO on Nasdaq in 2016.

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. More convenience and safety? The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! August 23, 2022. dstansberry@costellocreativegroup.com. What’s not to love?

Pharma 52